If it were a failure, you would have heard about it by now in form of announcement. There'd be no need for a webinar, just a statement explains: viral shedding not reduced enough, vaccine failure. Won't continue to trial phase 3. The end.
This is a platform tech with HPV along with it. More complicated. Likely, any collar is complicated and needs some explanation. Unlikely to be optimal outcome with millions that people want, but not failure.
Ann: HSV-2 Phase IIa Results Investor Webinar, page-20
-
- There are more pages in this discussion • 277 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |